Chlorzoxazone
A centrally acting skeletal muscle relaxant that depresses multisynaptic pathways in the spinal cord and brainstem to relieve spasm and associated pain from acute musculoskeletal conditions. It may cause hepatotoxicity, and rare cases of severe liver injury have been reported. It is indicated for short-term adjunctive use alongside rest and physical therapy.
Peso Molecular
169,5600 g/mol
LogP
1,80
TPSA
38,30 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
O=c1[nH]c2cc(Cl)ccc2o1
InChI
InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
Molecular Formula
C7H4ClNO2
HBD / HBA
1 / 2
Ligações Rotacionáveis
0
Átomos Pesados
11
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A centrally acting skeletal muscle relaxant that depresses multisynaptic pathways in the spinal cord and brainstem to relieve spasm and associated pain from acute musculoskeletal conditions. It may cause hepatotoxicity, and rare cases of severe liver injury have been reported. It is indicated for short-term adjunctive use alongside rest and physical therapy.
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Yes, Chlorzoxazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1371. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2733. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="chlorzoxazone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/chlorzoxazone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/chlorzoxazone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/chlorzoxazone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="chlorzoxazone"></drugfyi-drug>